Valeant Pharmaceuticals (VRX.TO) Buy, Sell or…

Home

Daily Stock Opinions and Ratings

Valeant Pharmaceuticals (VRX.TO)

0.00

-0.00 (0.00%)

39 watching

DON'T BUY

Has had problems. May not have reached bottom yet.

DON'T BUY

Too much controversy between analysts.

DON'T BUY

Their model price is $50. Could drop to a $38 lebel. It is a buy at $38.

WEAK BUY

Grows through acquisition which can be risky. Could go a little higher.

DON'T BUY

Price to sales is too expensive.

BUY

At a good price. Has several products.

BUY

Analyst report re: accounting, dropped the price. Oversold, so a good buy.

BUY

Very cheap. Volatile.

PAST TOP PICK

(Was a top pick on Mar 14 down 13.8%) Still likes. Has sales.

STRONG BUY

Volatile. Has many avenues of growth.

TOP PICK

Has been hit hard by an analysts rating. Not concerned. At a very good price. 21 X earnings.

BUY

Good pipeline. Good price.

TOP PICK

Likes their pipeline of new drugs. Good valuation.

WEAK BUY

Volatile, but gradually moving up. Moving out of generics. May be a little high.

PAST TOP PICK

(Was a top pick on Nov 26 down 8%) Still likes.

Showing 631 to 645 of 714 entries

Most Recent Experts

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Kevin Simpson

Capital Wealth Planning

Josh Brown, CEO, Ritholtz Wealth Management

Ritholtz Wealth Management

Michael Hakes - CFA, MBA

Murray Wealth Group

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Valeant Pharmaceuticals (VRX.TO)